Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 25,000 Shares of Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) CEO David Alan Campbell sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $51.60, for a total value of $1,290,000.00. Following the transaction, the chief executive officer now directly owns 257,054 shares of the company’s stock, valued at $13,263,986.40. The trade was a 8.86 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

David Alan Campbell also recently made the following trade(s):

• On Monday, October 28th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $53.54, for a total value of $1,338,500.00.
• On Friday, September 27th, David Alan Campbell sold 25,000 shares of Janux Therapeutics stock. The shares were sold at an average price of $46.31, for a total transaction of $1,157,750.00.

Janux Therapeutics Price Performance

JANX opened at $46.39 on Thursday. The firm has a market cap of $2.43 billion, a PE ratio of -39.65 and a beta of 3.52. The stock has a 50-day moving average price of $50.02 and a 200-day moving average price of $45.82. Janux Therapeutics, Inc. has a 1 year low of $7.79 and a 1 year high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The business had revenue of $0.44 million during the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The business’s quarterly revenue was down 82.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on JANX shares. Stifel Nicolaus began coverage on shares of Janux Therapeutics in a research report on Friday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a research report on Thursday, August 8th. Leerink Partners started coverage on Janux Therapeutics in a report on Friday, November 22nd. They set an “outperform” rating and a $79.00 target price on the stock. UBS Group initiated coverage on Janux Therapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $69.00 target price for the company. Finally, Scotiabank reduced their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a research note on Friday, August 9th. One analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and a consensus price target of $67.70.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Summit Securities Group LLC purchased a new stake in Janux Therapeutics during the 2nd quarter valued at $29,000. Amalgamated Bank grew its holdings in shares of Janux Therapeutics by 61.1% in the second quarter. Amalgamated Bank now owns 970 shares of the company’s stock worth $41,000 after acquiring an additional 368 shares during the period. Plato Investment Management Ltd purchased a new stake in Janux Therapeutics during the second quarter valued at $42,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock valued at $87,000 after acquiring an additional 339 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Janux Therapeutics in the second quarter worth about $151,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.